Regorafenib

BreastfeedingPediatric
  • TRADE NAME: Stivarga (Bayer)
  • INDICATIONS: Metastatic colorectal cancer, gastrointestinal stomal tumors
  • CLASS: Tyrosine kinase inhibitor
  • HALF-LIFE: 28 hours

FDA APPROVAL DATE: 09/27/2012

CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

Carbamazepine, Clarithromycin, CYP3A4 inducers and inhibitors, Grapefruit Juice, Itraconazole, Ketoconazole, Phenobarbital, Phenytoin, Posaconazole, Rifampin, St John's Wort, Telithromycin, Voriconazole

PREGNANCY CATEGORY: D

BLACK BOX WARNING
HEPATOTOXICITY

See full prescribing information for complete boxed warning.

Our database has 93 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN.
HAIR.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
HEMATOLOGIC.
NEUROMUSCULAR/SKELETAL.
OCULAR.
RENAL.
RESPIRATORY.
OTHER.


Page last updated 11/01/2022

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top